-
Pramlintide (trade name Symlin) is an
injectable amylin analogue drug for
diabetes (both type 1 and 2),
developed by
Amylin Pharmaceuticals (now a wholly...
- diabetes, obesity, and
other diseases.
Amylin produced three drugs:
Symlin (
pramlintide acetate),
Byetta (exenatide) and
Bydureon (exenatide
extended release)...
- most GLP-1
receptor agonists (liraglutide, exenatide, and others), and
pramlintide, all
diabetes medications are
administered orally and are thus called...
-
study combined metreleptin, a
version of the
human hormone leptin, and
pramlintide,
which is Amylin's
diabetes drug Symlin, into a
single obesity therapy...
-
Pramlintide/insulin A21G (development name ADO09) is a
combination of the
amylin analogue pramlintide and an
insulin analog. It is
being developed by...
- are
being developed as
therapies for
diabetes and obesity, and one,
pramlintide, has been FDA approved. The AMY1
receptor may be
activated by both amylin...
-
Rosiglitazone Troglitazone‡ Dual PPAR
agonists Aleglitazar† Muraglitazar§
Saroglitazar Tesaglitazar§
Amylin analogues and
DACRAs Cagrilintide§
Pramlintide...
-
Rosiglitazone Troglitazone‡ Dual PPAR
agonists Aleglitazar† Muraglitazar§
Saroglitazar Tesaglitazar§
Amylin analogues and
DACRAs Cagrilintide§
Pramlintide...
-
Rosiglitazone Troglitazone‡ Dual PPAR
agonists Aleglitazar† Muraglitazar§
Saroglitazar Tesaglitazar§
Amylin analogues and
DACRAs Cagrilintide§
Pramlintide...
- inflammasome.
Sulfonylureas – as
opposed to metformin, the thiazolidinediones,
pramlintide and
other newer treatments – may
induce hypoglycemia as a
result of excesses...
